Methyl 4-[4-(benzyloxy)phenyl]-3,3-dimethyl-4-oxobutanoate | 1055074-80-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl 4-[4-(benzyloxy)phenyl]-3,3-dimethyl-4-oxobutanoate
• 英文别名: methyl 3,3-dimethyl-4-oxo-4-(4-phenylmethoxyphenyl)butanoate
• CAS: 1055074-80-0
• 化学式: C₂₀H₂₂O₄
• 分子量: 326.392
• InChiKey: REAWVUWREPGDQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Methyl 4-[4-(benzyloxy)phenyl]-3,3-dimethyl-4-oxobutanoate 在 盐酸 、 palladium 10% on activated carbon 作用下， 以 甲醇 为溶剂， 以99%的产率得到Methyl 4-(4-hydroxyphenyl)-3,3-dimethyl-4-oxobutanoate
  参考文献：
  名称：

  4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists

  摘要：

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.037
• 作为产物：
  描述：

  (4-benzyloxy-phenyl)-trimethylsilanyloxy-acetonitrile 在 四丁基氟化铵 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 生成 Methyl 4-[4-(benzyloxy)phenyl]-3,3-dimethyl-4-oxobutanoate
  参考文献：
  名称：

  4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists

  摘要：

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.037

文献信息

• Gem-substituted &agr;v&bgr;3 antagonists
  申请人：Pharmacia Corporation

  公开号：US06531494B1

  公开（公告）日：2003-03-11

  The present invention relates to a class of compounds represented by the Formula I. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr;V&bgr;3 and/or the &agr;V&bgr;5 integrin.

  本发明涉及一类由化学式I表示的化合物，或其药学上可接受的盐，包括化合物I的药物组合物，并且选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法。
• Gem-substituted alpha v beta 3 antagonists
  申请人：——

  公开号：US20040043994A1

  公开（公告）日：2004-03-04

  The present invention relates to a class of compounds represented by the Formula I. 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or the &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I.1表示的化合物或其药学上可接受的盐，包括公式I中的化合物的药物组合物，以及选择性地抑制或拮抗αvβ3和/或αvβ5整合素的方法。
• GEM-SUBSTITUTED ALPHA V BETA 3 INTEGRIN ANTAGONISTS
  申请人：Pharmacia Corporation

  公开号：EP1313705A1

  公开（公告）日：2003-05-28
• US6531494B1
  申请人：——

  公开号：US6531494B1

  公开（公告）日：2003-03-11
• [EN] GEM-SUBSTITUTED alpha v beta 3 INTEGRIN ANTAGONISTS<br/>[FR] ANTAGONISTES DE L'INTEGRINE DOLLAR G(A)V DOLLAR G(B)3 GEM-SUBSTITUES
  申请人：PHARMACIA CORP

  公开号：WO2002018340A1

  公开（公告）日：2002-03-07

  The present invention relates to a class of compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively inhibiting or antagonizing the αvβ3 and/or the αvβ5 integrin.